FILE PHOTO: A medic administers COVAXIN, an Indian government-backed experimental COVID-19 vaccine, to a health worker during its trials, at the Gujarat Medical Education & Research Society in Ahmedabad, India, November 26, 2020. REUTERS/Amit Dave/File Photo
NEW DELHI (Reuters) - India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.
The news, announced by the drugs controller general of India (DCGI), was hailed by Prime Minister Narendra Modi and his ministers as a success in the country's self-reliance push.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
